At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 8, 2026 at 16:15 ET
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock. This capital raise follows a recent shelf registration and is intended to fund development of PH-762 and general working capital. The offering introduces potential near-term dilution.
- Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock
- The offering is being conducted pursuant to a shelf registration statement declared effective on July 1, 2024
- Proceeds will be used to advance PH-762 into a Phase 2b/3 trial and for general working capital
- H.C. Wainwright will receive a 3.0% commission on gross proceeds from sales
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access